Antibiotic prophylaxis in neutropenic patients: new evidence, practical decisions (Q34570947)

3 August 2017

1 reference

title

Antibiotic prophylaxis in neutropenic patients: new evidence, practical decisions (English)

1 reference

3 August 2017

0 references

Abigail Fraser

6

0 references

Leonard Leibovici

series ordinal

1

object named as

Leonard Leibovici

1 reference

3 August 2017

2

Mical Paul

1 reference

3 August 2017

5

Anat Gafter-Gvili

1 reference

3 August 2017

Michael Cullen

3

1 reference

3 August 2017

Giampaolo Bucaneve

series ordinal

4

1 reference

3 August 2017

Winfried V Kern

series ordinal

7

1 reference

3 August 2017

language of work or name

English

0 references

publication date

1 October 2006

1 reference

3 August 2017

1 reference

3 August 2017

107

1 reference

3 August 2017

8

1 reference

3 August 2017

1743-1751

1 reference

Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients

3 August 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22205

Oral norfloxacin for prevention of gram-negative bacterial infections in patients with acute leukemia and granulocytopenia. A randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22205

Selective bowel decontamination for the prevention of infection in acute myelogenous leukemia: a prospective randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22205

Oral enoxacin for infection prevention in adults with acute nonlymphocytic leukemia. The Enoxacin Prophylaxis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22205

Emergence of fluoroquinolone-resistant Escherichia coli at a cancer center

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22205

How do you choose antibiotic treatment?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22205

Antimicrobial susceptibility patterns of contemporary pathogens from uncomplicated urinary tract infections isolated in a multicenter Italian survey: possible impact on guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22205

Clostridium difficile ribotype 027, toxinotype III, the Netherlands

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22205

Prophylactic levofloxacin to prevent infections in newly diagnosed symptomatic myeloma: the TEAMM RCT

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22205

7 January 2021

Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22205

7 January 2021

Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22205

7 January 2021

2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22205

7 January 2021

Prophylactic Use of Ofloxacin in Granulocytopenic Patients with Hematological Malignancies during Post-remission Chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22205

7 January 2021

Prevention of bacterial and fungal infections in acute leukemia patients: a new and potent combination of oral norfloxacin and amphotericin B.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22205

7 January 2021

Prophylaxis of bacterial infections with ciprofloxacin in patients undergoing bone marrow transplantation.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22205

7 January 2021

Granulocyte colony-stimulating factor (G-CSF) with or without a quinolone in the prevention of infection in cancer patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22205

7 January 2021

Chemoprophylaxis with ciprofloxacin in ovarian cancer patients receiving paclitaxel: a randomized trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22205

7 January 2021

Antimicrobial prophylaxis in immunocompromised patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22205

7 January 2021

Reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: an EORTC double-blind placebo-controlled phase III study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22205

7 January 2021

Fluoroquinolone consumption and resistance in haematology-oncology patients: ecological analysis in two university hospitals 1999-2002.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22205

7 January 2021

Escherichia coli resistant to fluoroquinolones in patients with cancer and neutropenia.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22205

7 January 2021

Prevalence of ciprofloxacin-resistant Escherichia coli in hematologic-oncologic patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22205

7 January 2021

Bacteremia due to viridans group Streptococci with diminished susceptibility to Levofloxacin among neutropenic patients receiving levofloxacin prophylaxis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22205

7 January 2021

Urologic diseases in america project: trends in resource use for urinary tract infections in men.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22205

7 January 2021

Urologic diseases in America project: trends in resource use for urinary tract infections in women

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22205

7 January 2021

Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients: a systematic review and meta-analysis of randomized trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22205

7 January 2021

Fluoroquinolone resistance of Escherichia coli at a cancer center: epidemiologic evolution and effects of discontinuing prophylactic fluoroquinolone use in neutropenic patients with leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22205

7 January 2021

Impact of fluoroquinolone prophylaxis on reduced infection-related mortality among patients with neutropenia and hematologic malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22205

7 January 2021

Effect of discontinuing prophylaxis with norfloxacin in patients with hematologic malignancies and severe neutropenia. A matched case-control study of the effect on infectious morbidity.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22205

7 January 2021

Ciprofloxacin prophylaxis in patients with acute leukemia and granulocytopenia in an area with a high prevalence of ciprofloxacin-resistant Escherichia coli

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22205

7 January 2021

Oral ciprofloxacin plus colistin: prophylaxis against bacterial infection in neutropenic patients. A strategy for the prevention of emergence of antimicrobial resistance

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22205

7 January 2021

Prevalence and drug susceptibility of pathogens causing bloodstream infections in northern Italy: a two-year study in 16 hospitals.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22205

7 January 2021

Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22205

7 January 2021

A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22205

7 January 2021

An epidemic, toxin gene-variant strain of Clostridium difficile

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22205

7 January 2021

Poor infection control, not fluoroquinolones, likely to be primary cause of Clostridium difficile-associated diarrhea outbreaks in Quebec

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22205

7 January 2021

Identifiers

DOI

10.1002/CNCR.22205

1 reference

3 August 2017

1 reference